1. Scrip
  2. >>Focus On Asia
  3. >>China

Amoytop Acquires Skyline To Kickstart China 2025 M&A Activity

 
• By Dexter Jie Yan

Shanghai-listed Amoytop will take over the non-US operations of Skyline Therapeutics for $58m in total potential payments, in a deal revealing Amoytop’s ambitions to muscle into the gene therapy field.

Xiamen Amoytop Biotech has announced the first acquisition between Chinese biopharmas and pre-revenue biotechs in years. (Shutterstock)

Xiamen Amoytop Biotech, a Chinese biopharma focused on liver diseases and oncology, has stood out among its peers by becoming the first in years to acquire a pre-revenue compatriot biotech company.

Key Takeaways
  • Amoytop is acquiring the non-US operations of Skyline Therapeutics, a gene therapy specialist, for $58m in total potential payments, including $15m upfront.
  • Skyline's most advanced program in the clinic is SKG0106, an intravitreally delivered, adeno-associated virus-based gene therapy for the treatment of neovascular age-related macular degeneration

Shanghai-listed Amoytop said on 21 February it will take over the non-US operations of Skyline Therapeutics, a gene therapy specialist with offices in Shanghai, Hangzhou and Boston, for $58m in total potential

More from China

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Business